Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net income (loss)	$ (42,622)	$ (101,316)	$ (131,451)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Loss from Equity Method Investment in the Joint Venture			95,732
Depreciation and amortization	146,869	285,409
Amortization of capitalized software developed for sale	12	89
Accretion and changes in estimate, net	5,293	11,188
Equity compensation		23,914
Deferred income tax expense (benefit)		(28,590)	(15,806)
Amortization of debt discount and issuance costs		16,551	212
Contingent consideration	(550)	(3,000)
Gain on sale of businesses	(176)	(28,270)
Loss on extinguishment of debt	1,489	1,489
(Gain) loss on forward purchase contracts			2,435
Non-cash lease expense		14,629
Other, net		7,530
Changes in operating assets and liabilities:
Accounts receivable, net		114,052
Contract assets, net		(3,786)
Prepaid expenses and other		(48,382)	(2,136)
Accounts payable		(28,666)
Accrued expenses and other liabilities		27,687	48,640
Deferred revenue		36,029
Due to the Joint Venture, net			2,374
Net cash provided by (used in) operating activities		296,557
Cash flows from investing activities:
Capitalized expenditures		(126,432)
Acquisitions, net of cash acquired		(439,483)
Proceeds from sale of businesses		54,369
Investment in the Joint Venture			(609,818)
Investment in debt and equity securities of the Joint Venture			(278,875)
Other, net		1,100	3,621
Net cash provided by (used in) investing activities		(510,446)	(885,072)
Cash flows from financing activities:
Payments on Revolving Facility		(250,000)
Payments on Term Loan Facility		(50,000)
Proceeds from issuance of Senior Notes		325,000
Payments under tax receivable agreements with related parties		(20,691)
Receipts (payments) on derivative instruments		(14,810)
Employee tax withholding on vesting of equity compensation awards		(3,131)
Payments on deferred financing obligations		(6,547)
Payment of senior amortizing notes		(7,680)	(3,621)
Proceeds from exercise of equity awards		2,584	1,139
Proceeds from initial public offering, net of issuance costs			608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs			232,929
Proceeds from issuance of debt component of tangible equity units			47,367
Other, net		(6,454)	(1,421)
Net cash provided by (used in) financing activities		(31,729)	885,072
Effect of exchange rate changes on cash and cash equivalents		2,690
Net increase (decrease) in cash and cash equivalents		(242,928)
Cash and cash equivalents at beginning of period		410,405	3,409
Cash and cash equivalents at end of period	$ 167,477	$ 167,477	$ 3,409